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Introduction 
 
Handigodu Disease (HD) is a disorder of the 
osteoarticular system prevalent in several vil-
lages of two districts viz, Shimoga and Chick-
maglur in the state of Karnataka, southern In-
dia. The disease was first identified in a patient 
from Handigodu village in 1975, hence its name 
[1]. The data obtained during subsequent mul-
tidisciplinary study by Indian Council of Medical 
Research (ICMR) showed that HD is a Spondylo 
epi (meta) physeal dysplasia, inherited as an 
autosomal dominant trait [2]. The clinical pres-
entation of patients with HD has been identified 
into three sub types such as Arthritic type (Type 
I), Dysplastic type (Type II) and Dwarf type (Type 
III). All three sub types segregate in the same 
families implies often seen in the same family. 
The X-ray pictures showing the marked abnor-
malities are depicted in the Figure 1 and Figure 
2. 
 
The type I was characterized by late presenta-
tion of disease (45-50 years of age), character-
ized by pain in hip joints with difficulty in walk-
ing; and on examination these individuals had 
near normal height and body proportions 
(without significant truncal shortening), inability 
to sit cross-legged, fixed flexion deformity of 
hips and compensatory lumbar lordosis. Ra-
diologically these individuals showed character-
istic changes of osteoarthritis at the hip joints 
bilaterally, without any abnormality of spine or 
involvement of other bones. The type II of 
Handigodu disease was characterized by short 
stature, particularly truncal shortening. These 
patients were relatively younger (25-35 years of 
age) and the main complaint was inability to 
walk for longer distance.  The X-rays of these 
patients showed dysplastic femoral heads bilat-
erally, and varying degrees of platyspondyly. The 
type III Handigodu syndrome was marked by 
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dwarfism. They also had varying types of associ-
ated skeletal anomalies, particularly at the 
knees and hands. In these patients there was 
marked epiphyseal dysplasia at hips, knees, 
hands and wrists besides significant 
platyspondyly [2, 3]. The similarities between 
the Handigodu Disease and Mseleni joint dis-
ease reported from South Africa [3].  
  
Unpublished findings of alterations in calcium 
homeostasis were observed by the group of 
Dr.Teotia and colleagues (as part of the ICMR 
multidisciplinary study). Since there was a defi-
cit of study on mineral metabolism of bone with 
respect to hormones in HD. The calcium homeo-
stasis was studied by quantifying serum cal-
cium, phosphorus, parathyroid hormone and 
calcitonin in overnight fast state of serum. The 
calcium and phosphorus excretions for 24 hrs 
urine volume were also quantified to avoid inter-
ference of diurnal rhythms and food habbits. 
 
Materials and methods 
 
Subjects 
 
The HD affected patients clinically and x-ray 
radiological confirmed (Type I; n=19, Type II; n= 
28 and Type III; n=8) have been selected for 
this study within age group of 20-60 years old 
with their consent. The sixty three (Nonaffected; 
n=63) healthy individuals with age group of 20-
60 years old from the non related family mem-
bers of HD affected were enrolled in this study 
as controls. The patients were enrolled from the 
field. A door to door survey had been done of 
affected communities in all the affected villages 
of the Sagar taluk of District Shimoga in the 
state of Karnataka. X-ray examination had been 
done on all the family members (except preg-
nant women), in affected families with their con-
sent. Only cases confirmed by both physical 
examination and evaluation of X-rays were in-
cluded in the study, from amongst those who 
were willing to be admitted in the hospital for 
collection of 24 hour urine sample and over-
night fast serum. The X-ray pictures were eluci-
dated in Figure 1 and Figure 2. All the controls 
clinical and by x-ray diagnosis were normal. 
 
Ethics 
 
Both the affected and control subjects were 
explained the purpose of the study and written 
informed consent was obtained prior to the col-
lection of specimens. The study was approved 
Figure 1. X-Ray radiograph of hip joints from Handigodu Disease (HD) (A-E):  The radiograph osteoarthritis in hip joints 
of Type I subgroup are shown in A-C whereas dysplasia of hip joints from Type II and Type III subgroups are presented 
in D and E respectively. 
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Figure 2.  X-Ray radiograph of Lumbar spine from Handigodu Disease (HD) (A-C): Lateral view Lumbar spine showing 
varying degrees of platyspondyly in Type I (A), Type II (B) and Type III (C) subgroups. 
Figure 3.  Calcium and Phosphorus level of sera in 
Handigodu Disease (HD) (A-B):  Serum total Calcium 
(A) and Phosphorus (B) levels in HD subgroups Type I, 
Type II, and Type III compared with nonaffected family 
group. Note significantly decreased level of Calcium 
but unchanged Phosphorus in HD subgroups com-
pared to nonaffected family group. 
Figure 4.  The excretory level of Calcium and Phos-
phorus in Handigodu Disease (HD) (A-B): The 24 
hours urinary excretion of Calcium (A) and Phospho-
rus (B) levels in HD subgroups Type I, Type II, and 
Type III compared with nonaffected family group. 
There was significant decrease in level of Calcium 
but unchanged Phosphorus excretion in HD sub-
groups compared to nonaffected family group. 
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by institute’s human ethics committee.  
 
Biomarkers 
 
The subjects were asked to empty their bladder 
prior to the collection of 24 hrs urine and Hydro-
chloric acid (HCl) was used as preservative to 
avoid microbial deterioration. The serum sam-
ples were collected after an overnight fasting 
state. All of them (affected and control group) 
remained on their usual home diet during the 
24 hours urine collection. The serum and uri-
nary levels of calcium and phosphorus were 
determined by automated serum chemistry ana-
lyzer (Olympus). Calcium and phosphorus excre-
tions were related to 24 hrs urine volume col-
lected and creatinine levels excreted. The se-
rum iPTH and Calcitonin levels were determined 
by Immulite 2000 reagents. 
 
Statistical analysis 
 
The Data were analyzed by using SPSS pro-
gramme of Windows 2000. Statistical signifi-
cance was determined with one- way ANOVA 
followed by Bonferroni T-test and represented 
by ‘p’ value. The ‘p’ values were determined for 
different HD groups in comparison with non 
affected group as controls. The probability val-
ues, ≤ 0.05 were considered as statistically sig-
nificant. The p values were shown with respec-
tive data presented in Figures. 
 
Results 
 
The calcium homeostasis was studied by quan-
tifying calcium, phosphorus in urine and serum, 
and hormones from serum.   
 
The serum total calcium (mg/dl) levels 
(Nonaffected: 9.58 ± 0.39, Type I: 8.83 ±0.59, 
Type II: 8.74 ± 0.73, Type III: 8.61± 0.65) were 
found to be significantly less in affected group 
(Figure 3A). Interestingly, serum phosphorus 
(mg/dl) levels (Nonaffected: 3.77 ± 0.64,Type I: 
3.29 ± 0.54 Type II: 3.15 ± 0.66, Type III: 3.10 
± 0.43) were found to be remain unchanged 
(Figure 3B). The excretory levels of calcium in 
24 hrs urine volume (mg/24 hrs) (Nonaffected: 
103.16 ± 58.65, Type I: 89.51± 44.43, Type II: 
83.65 ± 49.13, Type III: 76.42± 39.81) were 
significantly lowered in affected groups and uri-
nary phosphorus levels (mg/24 hrs) 
(Nonaffected: 149.43 ± 39.77, Type I: 150.90 ± 
41.15, Type II: 182.59 ± 58.56, Type III: 
155.14± 73.43) found to be remain unchanged 
(Figure  4A and Figure 4B). 
 
Parathyroid hormone (iPTH) (pg/ml) levels in 
fasting state serum  between control and af-
fected groups (Nonaffected: 36.76 ± 20.82, 
Type I: 40.7±14.37, Type II: 34.04± 14.91, Type 
III: 35.15 ± 18.08) (Figure  5A) remain un-
changed, whereas calcitonin values (pg/ml) 
were significantly lowered  in HD affected sub-
groups (Nonaffected: 1.97 ± 1.16, Type I: 0.522 
± 0.372, Type II: 1.125± 1.034, Type III: 0.996 
± 0.488) (Figure 5B).  
 
The serum profile of other biochemical parame-
ters such as total protein, albumin and Alb/Glb 
ratio, the markers for nutritional deficiency were 
measured and found without significant differ-
ences.  Similarly, SGOT, SGPT, Urea, Creatinine 
and Alkaline Phosphatase values, the markers 
for liver function test and kidney function test 
were found to be remain unchanged in both the 
HD affected and unaffected members of HD 
families (data not shown). 
 
Discussion 
 
Parathyroid hormone (PTH) synthesized as 115- 
Figure 5. The Parathyroid hormone and Calcitonin 
level of sera in Handigodu Disease (HD) (A-B):  Serum 
Parathyroid hormone (A) and Calcitonin (B) levels in 
HD subgroups Type I, Type II, and Type III compared 
with nonaffected family group. There was significant 
decrease in level of Calcitonin and unchanged para-
thyroid hormone level in HD subgroups compared to 
nonaffected family group. 
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amino acid polypeptide called preproPTH in 
parathyroid cell by polyribosomes located within 
cell matrix of parathyroid gland. When the grow-
ing polypeptide chain ~20-30 amino acids long, 
the NH2- terminus of chain emerges first, and at 
this time two NH2 terminal methionine residues 
clevead by methionyl amino peptidase. As the 
nacent chain continues to grow the hydrophobic 
NH2 terminal sequence of preproPTH emerges 
and associates with membrane of endoplasmic 
reticulum. The sequence of 23 amino acids 
from prepro PTH is removed by cleavage of gly-
syl–lysyl bond near or in reticular membrane by 
enzymatic activity to proPTH (90 amino ac-
ids).The pro PTH arrives at Golgi apparatus and 
the trypsin like activity  accomplishes  conver-
sion of proPTH to PTH (iPTH of 1-84 amino ac-
ids) by removal of hexapeptide from NH2 termi-
nal sequence. The transport of PTH at the site 
of release by plasma membrane occurs through 
secretory granules. PTH is the predominant 
form of hormone stored in parathyroid gland [4]. 
 
Calcium is the physiologically important regula-
tor of parathyroid glandular activity for secretion 
of PTH. Other secretogogues have been identi-
fied for the regulation of PTH secretion, however 
their physiological role not understood com-
pletely. The secretion of PTH is inversely de-
pendent on concentration of extracellular cal-
cium. PTH increases the concentration calcium 
in blood and extracellular fluid (ECF) through its 
effects on bone, kidney, and gut. The negative 
feedback inhibition of parathyroid gland contrib-
utes to the regulation of ECF calcium concentra-
tions. Adenylate cyclase and cAMP appears to 
play as an intermediate in the regulation of PTH 
secretion in the control of calcium, however the 
exact role is not known. It may be that cAMP in 
some manner involved in the phosphorylation of 
substrate phosphoprotein in parathyroid gland. 
This substrate is membrane protein involved in 
the fusion of secretory granule with plasma 
membrane resulting in discharge of hormone to 
extracellular space. The PTH released to ex-
tracellular space by mechanism excitosis [4]. 
 
PTH is responsible for regulation of calcium lev-
els in blood and ECF through principal actions 
on kidney, bone and intestine. The parathyroid 
hormone acts on kidney to enhance the reab-
sorption of calcium and diminish the reabsorp-
tion of phosphate. PTH stimulates the formation 
of 1, 25 (OH)2D (vitamin D2) through its action 
on renal 1- α- hydroxylase, which in turn has 
direct biological effects on intestine. VitD2 in-
creases the absorption efficiency of dietry cal-
cium through intestine (4, 5]. 
 
PTH has several actions at different sites along 
the nephron. PTH enhances the calcium reab-
sorption at cortical site within the distal tubular 
portion and blocks the reabsorption of sodium, 
calcium, phosphate, and bicarbonate in proxi-
mal tubule. The iPTH decreases tubular reab-
sorption of phosphate by accelerating degrada-
tion of the Type-II sodium dependent phosphate 
transporter in the proximal tubules [5] The enzy-
matic activities of glucose-6-phosphate dehydro-
genase and reduced nicotine adenine dinucleo-
tide phosphate (NADPH) - diaphorase increases 
by exposure to PTH. The activity of latter enzyme 
may involve in the activation of Vitamin D me-
tabolites by 1- α- hydroxylation. PTH action in 
the kidey occurs through the formation of cAMP 
as second messenger cause to changes in cal-
cium transport. PTH stimulated adenylate cy-
clase activity is found at basolateral renal tubu-
lar cells adjacent to the renal capillaries. The 
intracellular receptor proteins for cAMP are 
found in brush borders of these cells at lumial 
side. The cAMP generated at basolateral region 
of cell migrates through cytoplasm to activate 
cAMP dependent kinases, in turn activate en-
zymes responsible for ion transport [4].  
 
In the skeleton, PTH stimulates to resorb the 
bone and subsequent release of calcium and 
phosphate into the circulation. PTH stimulates 
osteocytes, osteoclasts and their precursors. In 
hyperparathyroidism bone destruction and con-
comitant release of calcium, phosphate and 
other salts occurs. Osteocalsts can breakdown 
large volume of bone when stimulated at chroni-
cal levels; osteocytes resorb areas of surround-
ing calcified matrix stimulated by PTH. The ac-
tion of PTH on bone may largely mediated by 
intracellular cAMP. The production of cAMP and 
elevation of intracellular calcium levels are first 
events in the cascade of hormonal action. In the 
subsequent steps cAMP dependent protein 
kinases have been activated. The increase in 
the intracellular calcium level causes increased 
RNA synthesis and the release of lysosomal and 
other enzymes associated with bone resorption 
[4, 6]. 
 
The calcitonin is a potential calciotropic hor-
mone that has an inhibitory effect on osteoclas-
tic activity in-vitro and can also stimulate urinary 
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loss of calcium and phosphate [7]. The physio-
logical role of calcitonin in maintenance of bone 
mass is suggested by studies showing that con-
ditions associated with osteoporosis such as 
age and female sex show lower serum calci-
tonin level than observed in young individuals 
and in males [8,9,10]. Furthermore, the calci-
tonin administration increases bone mineral 
density (BMD) in postmenopausal women. Its 
effectiveness in treatment of osteoporosis has 
been shown in a randomized trial [11, 12, 13]. 
Calcitonin inhibits extracellular Ca2+ sensing, a 
potent antiresorptive signal, and by implication, 
calcitonin withdrawal should enhance Ca2+ 
sensing and limit resorption [14]. Calcium Sen-
sitive Receptor (CaSR) signaling is required for 
homeostasis of iPTH levels in serum [15, 16].  
 
The lowered concentrations of calcium and 
phosphorus in extra-cellular fluid lead to defec-
tive mineralization of organic bone matrix. The 
Defective bone matrix mineralization of newly 
formed bone and growth plate cartilage leads to 
characteristic morphological and clinical signs 
of rickets, while at sites of bone remodeling, it 
causes osteomalacia [17, 18]. However, despite 
negative calcium and phosphorus balance clini-
cal and radiological signs of rickets and osteo-
malacia have not been observed in HD. It is also 
paradoxical that in spite oflow levels of serum 
and 24 hours excretion of calcium, the serum 
iPTH levels were normal in HD subgroups.  On 
the basis of results observed, we can provide 
the following hypothesis in the HD perspective 
to calcium homeostasis.  1)  During subsequent 
studies of ICMR on HD observed no changes in 
Vitamin D3 level (30.4 ± 5.8 ng/ml), values were 
in laboratory reference ranges. Hence these 
results suggest suspicious over possible muta-
tion of Vitamin D Receptor in HD. The uptake of 
calcium from intestine may disturb causing low 
level of calcium in serum, subsequently leads to 
low level excretion. 2) The low level of calcium 
without change in PTH causes diminished secre-
tion of calcitonin. Hence observed hypocalci-
tonemia may be an epiphenomenal. 3) Calci-
tonin has antiresorption effect on bone; the ob-
served low calcitonin in HD may imply 
reosrption of bone leading to deformity and 
causes hypocalciuria and hypocalcaemia. 4) 
The observed calcitonin withdrawal should en-
hance Ca2+ sensing, limit resorption, and in-
creased extracellular calcium. Surprisingly in HD 
the calcium level is low and has no effect on 
PTH homeostasis. This result lead to suspicious 
over possible mutation of Calcium Sensitive 
Receptor (CaSR).  
 
The peptide bound increased Pro / Hyp ratio 
suggests HD may involve reduced bone turnover 
or a possible defective hydroxylation of prolyl 
residues during posttranslational modification 
of collagen molecule biosynthesis [19, 20]. We 
have earlier reported deficiency of magnesium 
in HD may cause defect in bone matrix forma-
tion [21]. The varied involvement of these fac-
tors may result in different subtypes observed in 
HD. The scientific name of the disease is 
Spondylo-epi-(meta) physeal Dysplasia, Auto-
somal Dominant variety, Handigodu syndrome. 
The same has been listed in the International 
Classification of Skeletal Dysplasias. It is consid-
ered to be genetically determined. The disease 
is highly prevalent in a localized pocket, re-
stricted to a particular geo-ethnic community. It 
would be interesting to carry out a follow up 
study to evaluate it as an early biomarker of the 
disease.  
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